Phase 2 Clinical Trial Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With the Genomically-Targeted Agent Erlotinib in Combination With Temozolomide
Phase of Trial: Phase II
Latest Information Update: 17 Feb 2018
At a glance
- Drugs Erlotinib (Primary) ; Temozolomide (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- 08 Feb 2017 Planned End Date changed from 1 May 2020 to 31 May 2020.
- 08 Feb 2017 Planned primary completion date changed from 1 Nov 2019 to 30 Nov 2019.
- 12 Aug 2016 Status changed from not yet recruiting to recruiting.